Inclusion Criteria:

- Signed written informed consent

- Male or female ≥ 18 years of age

- Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

- Metastatic colorectal carcinoma not suitable for curative-intent resection-
Availability of tumor sample (or able and willing to provide tumor sample) for EGFR
assessment

- Presence of at least one lesion measurable unidimensionally by CT scan or MRI.
(Target lesion(s) must not lie within an irradiated area)

- Karnofsky performance status of > 80 at study entry

- Leucocytes ≥ 3.0 x 10 9/L and neutrophils ≥1.5 x 10 9/L, platelets ≥ 100 x 10 9/L,
and hemoglobin ≥ 9 g/dL.

- Bilirubin ≥ 1.5 x ULN

- ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis are present)

- Serum creatinine ≤ 1.5 x ULN

Exclusion Criteria:

- Brain metastasis (known or suspected)

- Previous chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed
if the chemotherapy treatment free interval is > 6 months.

- Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study
entry

- Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
indicated in the study protocol

- Any investigational agent(s) within 4 weeks prior to entry

- Previous exposure to EGFR-pathway targeting therapy

- Clinically relevant coronary artery disease or a history of a myocardial infarction
within the last 12 months

- Acute or subacute intestinal occlusion or history of inflammatory bowel disease

- Pre-existing neuropathy > grade 1. In case of prior oxaliplatin containing adjuvant
chemotherapy: pre-existing neuropathy ≥ 1.

- Known grade 3 or 4 allergic reaction to any of the components of the treatment.

- Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ
of the cervix. (Patients with a previous malignancy but without evidence of disease
for ≥ 5 years will be allowed to enter the trial)

- Pregnancy or lactation

- Inadequate contraception (male or female patients) if of childbearing or
procreational potential

- Known drug abuse/ alcohol abuse

- Legal incapacity or limited legal capacity

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent